| 5.1 Smoking cessation |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
| 5.2 Serious adverse events |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
| 5.2.1 1 year |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
| 5.2.2 6 months |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
| 5.3 Carbon monoxide (ppm) |
3 |
348 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.92 [‐1.71, ‐0.13] |
| 5.3.1 Change from baseline |
2 |
309 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.90 [‐1.70, ‐0.10] |
| 5.3.2 Absolute values at follow‐up |
1 |
39 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.66 [‐6.65, 3.33] |
| 5.4 Heart rate |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.4.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.5 Systolic blood pressure |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.5.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.6 FeNO (ppb) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.6.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.7 FEV1 (l) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.7.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.8 FVC (l) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.8.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.9 FEV1/FVC |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.9.1 12 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.10 NNAL (pg/mg creatinine) at 24 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5.11 Product use at 6+ months |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
